

Nothing is simpler than Banamine[®] Transdermal for pain and fever relief in cattle.





BANAMINE **TRANSDERMAL INDICATIONS:**

- For the control of pyrexia associated with acute mastitis
- For the control of pyrexia associated with BRD
- For the control of pain associated with foot rot

Now approved for fever control due to mastitis

FDA has now approved Banamine Transdermal for fever control due to mastitis with a short, 48-hour milk withhold time. It is the newest example of Merck Animal Health's commitment to improve animal care and animal caregiver options through innovation.



Visit BanamineTD.com for more information.

THE FIRST AND ONLY POUR-ON FOR RELIEF OF PAIN AND FEVER

Pain and fever can cause cattle to go off feed. But new, easy-to-use Banamine® Transdermal (flunixin transdermal solution) helps get 'em back where they belong.

FDA-approved to control pain due to foot rot and fever due to BRD and mastitis. Banamine Transdermal is the only non-steroidal anti-inflammatory (NSAID) cattle product available with a convenient pour-on route of administration.

Uniquely designed to go to work quickly

Banamine Transdermal controls pain and fever quickly. Studies show that a single dose is absorbed into the bloodstream within minutes¹ and has long duration of activity at the site of inflammation², giving cattle the best opportunity to be healthy and productive.

Easy to dose

The pre-calibrated packaging helps ensure the right dose is given every time. The unique bottle design allows for proper topical application along the animal's back. The red-colored solution makes it simple to accurately and guickly measure the dose volume for each animal.

1. Data on file: EX-05331-00

2. Lees P. Higgins AJ. Flunixin inhibits prostaglandin E2 production in equine inflammation. Res Vet Sci. 1984; 37:347-349.

IMPORTANT SAFETY INFORMATION: NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. Milk that has been taken during treatment and for 48 hours after treatment must not be used for human consumption. Cattle must not be slaughtered for human consumption within 8 days of the last treatment. Not for use in replacement dairy heifers 20 months of age or older or dry dairy cows; use in these cattle may cause drug residues in milk and/or calves born to these cows or heifers. Not for use in beef and dairy bulls intended for breeding over 1 year of age, beef calves less than 2 months of age, dairy calves, and veal calves. Do not use within 48 hours of expected parturition. Approved only as a single topical dose in cattle. For complete information on Banamine® Transdermal, see accompanying product package insert.

Easy to apply


Patented delivery eliminates the need for IV administration, so you can make quick work of treatment with this simple pouron. Its needle-free and efficient administration means there are less labor and supplies than what is associated with injectable administration. The result is a decreased cost per treatment, due to the reduction in time spent treating animals.

Easy on animals

Managing fever and pain is important to animal welfare. Transdermal application requires less handling, resulting in less stress on the animals. Banamine Transdermal is specially formulated to rapidly absorb through the skin and into the bloodstream¹.

Plus, with needle-free, transdermal administration, there is no risk of injection site lesions.





DOSING AND ADMINISTRATION MADE EASY

Four simple steps for this new route of administration



Step 1: Determine the animal's body weight and select the correct dose using the bottle's dosing chamber, which is calibrated in pounds of body weight. Banamine Transdermal is labeled to be administered once at a dose of 3 mL per 100 pounds on dry skin.




Step 2: On first use, remove the cap and peelable seal from the dosing chamber. Do not remove the cap from the storage bottle.



Step 3: Hold the bottle upright and at eye level while slowly and gently squeezing the bottle to fill the dosing chamber to the selected mark.



Step 4: Pour the measured volume on the midline of the animal's back extending from the withers to tail head. Localized application to smaller areas should be avoided.



FREQUENTLY ASKED QUESTIONS ABOUT **ADMINISTERING BANAMINETRANSDERMAL**

What is the meat withdrawal and milk withhold times?

Banamine Transdermal requires a 48-hour milk discard and an 8-day pre-slaughter withdrawal period following treatment.

Should the dose be adjusted based on air temperatures?

There is no need to adjust the dose. Clinical effectiveness was demonstrated over a range of environmental temperatures expected under field conditions. While studies demonstrated peak plasma flunixin concentrations were consistently lower when the pour-on product was administered in cold temperatures vs. hot temperatures, the bioavailability is the same³.

Is there concern over animals licking Banamine Transdermal from treated animals?

No. A study where animals were allowed to self-lick or lick pen mates demonstrated a lower rate and extent of absorption when compared to the animals prevented from licking. However, no dose adjustment is needed to account for the effect of licking because substantial evidence of effectiveness was demonstrated in animals that were allowed to lick³.

How long should animals be protected from rain exposure after treatment? Six hours³.

3. Product label.



Users should wear eye protection, such as safety glasses or goggles, to prevent eye contact. Chemical-resistant gloves and appropriate clothing, such as a long-sleeved shirt and pants, should be worn to prevent skin contact and/or drug absorption. Wash hands after use.



SAFE AND EFFECTIVE FOR PAIN AND FEVER³

CONTROL FEVER ASSOCIATED WITH MASTITIS

Banamine Transdermal was determined to be safe and effective in controlling fever with acute mastitis.

Trial setup

A multi-site field study was conducted with purebred and crossbred lactating dairy cows (primarily Holstein) between 2 and 12 years of age. Depending on the facility, cows were housed indoors or on pasture. Cows were not restricted from licking, and in most cases, were free to contact and interact with at least one other cow. They were also protected from rain and misting systems and did not have access to a cow brush.

Six hours after treatment, rectal temperature was measured. An animal was considered a treatment success if rectal temperature was reduced by $\geq 2^{\circ}F$.

Results

Treatment success was 95 percent for animals receiving Banamine Transdermal (p<0.0001) compared to 35 percent of untreated controls. There were no treatment-related adverse reactions within six days following dosing.

CONTROL FEVER ASSOCIATED WITH BRD

Banamine Transdermal was determined to be safe and efficacious in controlling fever associated with BRD.


Trial setup

Field studies were conducted in four states with 251 total animals enrolled and diagnosed with BRD. At enrollment, rectal temperatures ranged from 104.5 to 107.8°F. Animals received either 3 mL per 100 pounds of Banamine Transdermal or a placebo. No antimicrobials were administered.

Six hours after treatment, rectal temperature was measured and treatment sites were observed for abnormalities. An animal was considered a treatment success if rectal temperature was reduced by $\ge 2^{\circ}F$.

Results

Treatment success was 58.3 percent for animals receiving Banamine Transdermal compared with 6.1 percent for the placebo group (p<0.001). Treatment sites were considered normal in animals treated with Banamine Transdermal.



CONTROL PAIN ASSOCIATED WITH FOOT ROT

Banamine Transdermal was determined to be safe and efficacious in controlling pain associated with foot rot.

Trial setup


Studies were conducted in two states with 30 steers enrolled weighing between 717 and 1,085 pounds. Animals were experimentally induced with foot rot infection in the right front limb. After 48 hours, animals were given either Banamine Transdermal (3 mL per 100 pounds) or placebo (dyed saline). No antimicrobials were administered.

At the time of treatment and six hours after treatment, lameness scores and pressure mat gait parameters of both maximum total force and contact area were measured. An animal was considered a treatment success if the lameness score decreased by more or equal to one point.

Results

At site 1, lameness score treatment success was 100 percent and significantly different for animals receiving Banamine Transdermal. This compares with 6.67 percent for the placebo group. The mean change in maximum total force and mean change in contact area were significantly different (p<0.0001) and higher in the flunixin transdermal solution-treated group compared to the placebo group.


At site 2, the lameness score treatment success rate was 93.3 percent and significantly different for the animals given Banamine Transdermal. This compares with 53.3 percent for the placebo group. The mean change in maximum total force and mean change in contact area were significantly different (p= 0.0002 and p<0.0001,



respectively) and higher in the flunixin transdermal solution-treated group compared to the placebo group.

The marked increases in both maximum total force and total contact area at both study sites were clinically interpreted as animals able to plant their affected foot in a more normal fashion and bear more weight on the affected limb, supporting clinical improvement in lameness as a result of less pain.

While the cause of lameness should always be treated, this study demonstrated Banamine Transdermal significantly reduced lameness, which is an expression of pain.



Product Information

Approved by FDA under NADA # 141-450 **Banamine**[®] Transdermal

(flunixin transdermal solution)

Pour-On for Beef and Dairy Cattle 50 mg/mL

Non-Steroidal Anti-inflammatory Drug

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. DESCRIPTION: Each milliliter of Banamine Transdermal nour-on contains 50 mo flunixin lequivalent to 83 ng flunixin megluminel, 150 mg pyrrolidone, 50 mg L-menthol, 500 mg progylene dicaprylate/dicaprate NF, 0.20 mg FD&C Red No. 40, and glycerol monocaprylate NF qs. ne glyco


INDICATIONS: Banamine Transdermal pour-on is indicated for the control of pyrexia associated with bovine respiratory disease and acute bovine mastitis, and the control of pain associated with foot

rot in beef cattle 2 months of age and older and dairy cattle. Not for use in beef and dairy bulls intended for breeding over 1 year of age, replacement dairy heifers over 20 months of age, dry dairy cows, dairy calves, or veal calves

DOSAGE AND ADMINISTRATION: Apply only once at a dose of 3.3 mg flunixin per kg body

weight (1.5 mg/lb; 3 mL per 100 lbs) topically in a narrow strip along the dorsal midline from the weight in the initial of the other oth after dosing because effectiveness has not been evaluated under wet hide conditions

Practice the Administration and Overfill Reduction Instructions a few times to become familiar with operating the package before dosing animals.




Pour the measured volume on

the dorsal midline from withers to tail head. Application to a small area should be avoided

A small amount of liquid will remain on the walls of the chamber, but the chamber is calibrated to account for this

OVERFILL REDUCTION INSTRUCTIONS




inside the dosing chambe



Squeeze and release the bottle repeatedly Product will return to the bottle through the transfer tube

Figure 1 - Recommended pour-on location



CONTRAINDICATIONS: NSAIDs inhibit production of prostaglandins which are important in Signaling the initiation of parturition. The use of fluminin can delay parturing into an or important in signaling the initiation of parturition. The use of fluminin can delay parturition and prolong labor which may increase the risk of stillbirth. Do not use Banamine Transfermal pour-on within 48 hours of expected parturition. Do not use in animals showing hypersensitivity to flumixin meglumine.

USER SAFETY WARNINGS: Not for use in humans. Keep out of reach of children. Flunixin transdermal solution is a potent non-steroidal anti-inflammatory drug (NSAID), and ingestion may cause gastrointestinal irritation and bleeding, kidney, and central nervous system effects.

This product has been shown to cause severe and potentially irreversible eye damage (conjunctivitis, iritis, and corneal opacity) and irritation to skin in laboratory animals. Users should wear suitable eye protection (face shields, safety plasses, or googles) to prevent eve contact; and chemical-resistant

BanamineTD.com • 800-521-5767 US-FIN-230100003 02/2023

gloves and appropriate clothing (such as long-sleeve shirt and pants) to prevent skin contact and/or drug absorption. Wash hands after use

In case of accidental eye contact, flush eyes immediately with water and seek medical attention. If wearing contact lenses, flush eyes immediately with water before removing lenses. In case of accidental skin contact and/or clothing contamination, wash skin throoughly with soap and water and launder clothing with detergent. In case of ingestion do not induce vomiting and seek medical attention immediately. Probable mucosal damage may contraindicate the use of gastric lavage. Provide product label and/or package insert to medical nersonnel

Withdrawal Periods and Residue Warnings: Mik that has been taken during treatment and for 48 hours after treatment must not be used for human consumption. Cattle must not be slaughtered for human consumption within 8 days of treatment. Not for use in replacement dairy heifers 20 months of age or older or dry dairy cows; use in these cattle may cause drug residues in calves born to these cows or heifers. Not for use beer calves less than 2 months of age, dairy calves, and veal calves. A withdrawal period has not been established for this product in pre-ruminating calves. Approved only as a single topical dose in cattle. Repeated treatments may result in violative residues in milk or in edible tissues

PRECAUTIONS: As a class, cyclo-oxygenase inhibitory NSAIDs may be associated with gastrointestinal, renal, and hepair torigits. Sensitivity to drug-associated adverse events varies with the individual patient. Patients at greatest risk for adverse events are those that are dehydrated, on concomitant diuretic therapy, or those with renal, cardiovascular, and/or hepatic dysfunction. Banamine Transdermal should be used with caution in animals with suspected pre-existing pastric revisions or ulcerations. Concurrent administration of other NSAIDs, corticosteroids, or protentially nephrotoxic drugs should be avoided or used only with careful monitoring because of the potential increase of adverse events. Banamine Transdermal is approved only as a single topical dose. The safety of repeated treatment has not been evaluated.

NSAIDs are known to have notential effects on both parturition (see Contraindications) and the estrous INSANUS are known to nave polennia erfects on doint parturnion see Contraindicetoms and the extra cycle. There may be a delay in the onset of estrus if fluxikin is administered during the prostaglandin phase of the estrus cycle. INSANDs are known to have the potential to delay parturition through a tocolytic effect. The use of NSAIDs in the immediate post-partum period may interfere with uterine involution and expulsion of fetal membranes. Cows should be monitored carefully for placental retention and metritis if Banamine Transdermal pour-on is used within 24 hours after parturition

Not for use in beef and dairy bulls intended for breeding over 1 year of age because reproductive safety has not been evaluated. CLINICAL PHARMACOLOGY: Flunixin meglumine is a nonsteroidal, anti-inflammatory drug. It is

a weak acid (pKa = 5.82)¹ which exhibits a high degree of plasma protein hinding lapproximately 1996). However, free (unbound) drug appears to readily partition into body tissues (Vss predictions range from 297 to 782 mL/kg).²⁴ In cattle, elimination occurs primarily through billary excretion.

Flunixin persists in inflammatory tissues⁸ and is associated with anti-inflammatory properties which extend well beyond the period associated with detectable plasma drup concentrations.^{4,6} Therefore, prediction of drug concentrations based upon the estimated plasma terminal elimination half-life will likely underestimate both the duration of drug action and the concentration of drug remaining at the site of activity.

Pharmacokinetic properties of flunixin transdermal solution in cattle administered at a dose of Transcission of the properties of halding to making a distance meta-analysis of the communication of the distance of the second evidence of effectiveness was demonstrated in animals that were allowed to lick.

Table 1. Average (+/- standard deviation (SDI) PK parameters after a single administration of flunixin transformal solution at a dose of 2.5 mg/kg in cattle that were either allowed to lick or prevented from allo- and self-licking (n = 24/group).

PK parameter	Non-licking		Licking	
	Mean	± SD	Mean	± SD
C _{max} (ng/mL)	1496	769	N/A	N/A
Concentration at 2 h*	1282	533	1072	353
Tmax (h)	1.29	0.464	N/A	N/A
AUC _{2-last} (ng*h/mL)	7499	2131	6827	4672
T1/2 (h)	8	2	9	6

* First blood level in the licking group was taken at 2 hours post-dose First blood sample in non-licking group was taken at 0.25 hours post-dose

Cmax: Maximum observed plasma concentration

Timac: Time at which Cinex was observed AUC21err: Area under the plasma concentration versus time curve measured between 2 hours and the time of the last quantifiable concentration

Tug: Terminal elimination half-life

Absorption of flunixin transdermal solution in cattle is dependent on environmental temperature. The effect of temperature on flunixin absorption was tested in temperatures ranging from 15.3 to 20.1 °F (average low in the coldest study) to 80 to 100 °F (average high in the warmest study). Flunixin concentrations were consistently lower when the pour-on product was administered in a cold temperature l'arther than hot temperature le nivien men de participation en product real automatica en la con-demonstrated over the range of environmental conditions expected under field conditions. No dose adjustments are necessary due to environmental temperature.

References:

usson M, Anler EL. Gas chromatographic analysis of flunixin in equine urine after extractive 1 .loh: Johnston M, Kind LL, Ossennotogi philosophysis of noninan in equine animal and exception of the exception of the

flunixin in bovine plasma and pharmacokinetics after single and repeated doses of the drug. Am J Vet Res. 1995; 56:489-495. 3. Anderson KL, Neff-Davis CA, Davis LE, Bass VD. Pharmacokinetics of flunixin meglumine in lactating

cattle after single and multiple intramuscular and intravenous administrations. Am J Vet Res. 1990; 51.1464-1467

A. Odensvik K. Pharmacokinetics of flunixin and its effect on prostaglandin F2a metabolite concentrations after oral and intravenous administration in heifers. J Vet Pharmacal Ther. 1995;18:254-259.

5. Hardee GE, Smith JA, Harris SJ. Pharmacokinetics of flunixin meglumine in the cow. Res Vet Sci. Barbard G., Simma G., Harris G. H

Sci. 1984; 37:347-349

TARGET ANIMAL SAFETY: In a target animal safety study in 32 six-month old beef cattle (16 For the restrict matter spectra of the second seco was conducted under warm environmental conditions (70 °F to 80 °F on dosing days). One animal in We conducted under water environmental conductors for the door for to do any doas of the terminal in the 3X group and three animals in the 5X group exhibiting twisting, kicking, rubbing on the fence, and or prancing, starting 5 to 15 minutes after dosing and lasting up to an hour after dosing on both Days 2 and 3. Two 5X animals had positive fecal occult blood on one of three post-treatment days, and one 5X and 3. Two GA animas ned positive reader to book of hole of hole of hole of hole of hole of the positive reading and book and the read occurb blood was found in the urine of three animals: one 5X animal on Day 1, one 5X animal on Day 3, and one 3X animal on Day 3. Test article-related pathology changes included a dose-related increase in the incidence and severity of abomasal erosions and ulcerations; and inflammatory cell infiltrates, epidermal necrosis and small areas of dermal necrosis at the application site. The abomasal lesions correlated with fecal occult blood in three 5X animals. There were no animals with any other evidence of gastrointestinal bleeding or clinical signs of abomasal ulceration during the study.

Application site reactions, including dandruff/skin flakes, hair damage (thin, broken, brittle hair), and reprincipant are received in a second guardination and makes, for a bungle fully break of the form of and six in thickening were observed in effectiveness and row supportive studies. The application site reactions were first observed around three to seven days post-dosing and lasted for about 14 days. These reactions were cosmetic in nature and generally resolved without treatment. A pharmacokinetic evaluation demonstrated that the systemic exposure of flupixin is markedly A promotonic de contractor de montonica de la contractor by reproductive safety studies conducted for the approval of BANAMINE (flunixin meglumine injection) cattle NADA 101-479

EFFECTIVENESS:

Clinical field studies - bovine respiratory disease

Pharmacokinetic studies established that the absorption of flunixin administered transdermally to cattle is highly dependent on environmental temperature. Therefore the effectiveness of flunixin transdermal solution for the control of pyrexia associated with bovine respiratory disease was demonstrated under a range of environmental temperatures in two studies: a field study conducted at four geographic locations (California, Kansas, Nebraska, and Texas) under moderate environmental temperatures (average temperatures ranged from 42 °F to 74 °F on enrollment days) and a field study conducted at a single site (Nebraska) under cold environmental conditions (average temperatures ranged from 2 °F to 20 °F on enrollment days). In both studies, cattle were housed in groups and were not prevented from licking.

In both studies, cattle exhibiting clinical signs of BRD and having a rectal temperature of at least 104.5 °F were enrolled. A total of 235 cattle in the multi-location field study and 50 cattle at the single site field study were administered either flunixin transdermal solution (3.3 mg/kg BW) or an equivalen volume of dyed saline as a pour-on once on Day 0. Six hours after treatment, rectal temperatures were measured. The treatment success rate of the flunixin transdermal solution-treated group was compared to the treatment success rate in the dyed saline control group. A treatment success was compared with characteristic and the minimum of the same compared and the minimum subcess was defined as a dopt in rectal temperature of a 2^{-p} in an individual animal. In the multi-location study, the treatment success rate was significantly different (p < 0.0001) and higher for the flunixin transformal solution-treated group 170/120, 58.3% I compared to the dyad saline control group (7/115, 6.1%). In the single site study, the treatment success rate was significantly different (p = 0.0002) and higher for the flunixin transdermal solution-treated group (19/25, 76%) compared to the dyed saline control group (4/25, 16%).

Induced infection model studies – foot rot

The effectiveness of flunixin transdermal solution for the control of pain associated with foot rot in beef and dairy cattle was demonstrated under a range of environmental temperatures in two studies an induced infection model study conducted in Nebraska with temperatures ranging from 61 °F to 85 °F on the day of enrollment and treatment; and an induced infection model study conducted in Kansas with temperatures ranging from 27 °F to 53 °F on the day of enrollment and treatment. In both studies, cattle from both treatment groups were commingled in pens and were not prevented from licking

In each study, cattle were challenged by subcutaneous injection of a culture of Fusobacterium in eccentrality, certer where channels of your control on increasing the control of the control associated with foot rot based on lameness, interdigital lesion, and interdigital swelling criteria. Pressure mat gait parameters maximum total force [kgf] and contact area [cm²] were also measured at enrollment. A total of 30 cattle at each site were administered either flunixin transdermal solution (3.3 mg/kg BW) or an equivalent volume of dyed saline as a pour-on once on Day O. Six hours after treatment, lameness scores and pressure mat gait parameters maximum total force and contact area were measured.

Effectiveness was determined independently at each site based on treatment success rates at six hours after treatment; and the change in maximum total force and contact area between enrollment and six hours after treatment. A treatment success was defined as a decrease in lameness score by ≥ 1 (scale 1 to 5, with enrollment of animals with lameness score \geq 3) from the enrollment lameness score. The treatment success rate of the flunish transformal solution-treated group was compared to the treatment success rate in the dyed saline control group at both sites.

Changes in biometric gait parameters were also compared between the treatment groups

In the Nebraska study, the treatment success rate was significantly different and higher for the In the reactions of the f, the technical spectra for the Versian production for the technical matrix for the function transferred and the first field of the first f group (43.08 kgf and 16.76 cm²) compared to the dyed saline control group (-4.14 kgf and -2.70 cm²). In (and) Hostoria in the feature of the component of the operation of the operation of the operation of the operation of the feature of the operation of th statistically significantly different (p=0.0002 and p<0.0001, respectively) and higher in the flunixing transdermal solution-treated group (34.32 kgf and 16.38 cm²) compared to the dyed saline control group (-0.54 kgf and -0.96 cm²).

Clinical field study - acute bovine mastitis

The effectiveness of flunixin transdermal solution for the control of pyrexia associated with acute bovine mastitis was demonstrated under a range of environmental temperatures (37.4 °F to 86 °F) towne most to was demonstrated under a range or environmental emperators for (1,000 T) in a multi-site fast davdy conducted in France, Germany, and Spain. Cattle were housed in a manner which did not prevent them from licking themselves or other cows. Lactating dairy cows were enrolled when they exhibited acute signs of mastitis in one or two quarters (based on an evaluation of udder firmness, swelling, and pain), milk characteristics consistent with mastitis, and a rectal temperature of at least 104 °F.

Enrolled cows were administered either flunixin transdermal solution (3.3 mg flunixin/kg BW) or an equivalent volte dominante se international and a solution to the provident of the solution to perform the two performance in the terminal solution in the human terminal solution in the terminal solution to the terminal solution in the dyed saline control group. A terminal solution to the terminal success rate was significantly different (p < 0.0001) and higher in the fluxixin transdermal solution solution. treated group (61/64, 95%) compared to the dyed saline control group (23/66, 35%)

CONTACT INFORMATION:

For technical assistance or to report a suspected adverse drug experience, call: 1-800-211-3573. For customer service or to request a Safety Data Sheet (SDS), call: 1-800-521-5767. For additional Banamine Transdermal pour-on information go to www.BanamineTD.com. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at www.fda.gov/reportanimalae.

HOW SUPPLIED: Banamine Transdermal nour-on is available in 100-ml (NDC 0061-4363-01), 250-mL (NDC 0061-4363-02), and 1-L (NDC 0061-4363-03) bottle:

STORAGE INFORMATION: Store at or below 30°C (86°F). Use within 6 months of first opening.

For Patent information: http://www.merck.com/product/patent/home.html. Approved by FDA under NADA # 141-450. Use Only as Directed.

Copyright © 2017–2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. ormulated in Germany. Distributed by: Intervet Inc. d/b/a Merck Animal Health. Madison. NJ 07940

Rev. 10/2022



Copyright ©2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.